A Phase 2 interventional study of bimekizumab in Moderate to Severe Plaque Psoriasis, sponsored by UCB Biopharma SRL. Completed at 11 sites in 4 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing bimekizumab in Psoriasis — 4 open to participants now, 5 under way, 3 of them phase 3. bimekizumab · Psoriasis.
Among the 20 studies testing bimekizumab in Psoriasis, this one is the 17th largest by enrollment, is one of 2 that started in 2021, is one of 6 in phase 2, and was the 12th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 20 studies testing bimekizumab in Psoriasis are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Canada, China and 10 more countries
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–45
University Hospital, Rouen · Sites in France
Ages 18–60
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 161 across the 20 interventional studies. Of the 15 that completed or were terminated, 12 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 20 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
26 studies in Psoriasis by UCB S.A.: 1 open now, 2 under way, 2 of them phase 3. Of 24 finished, 19 (79%) have results posted.
Among the 26 studies in Psoriasis by UCB S.A., this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 21st registered.
UCB S.A.’s Psoriasis studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing bimekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 26 in Psoriasis:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit and:
i. facial involvement ii. Clinically relevant genital involvement iii. Clinically relevant hand and foot involvement
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants randomized to this arm will receive bimekizumab (BKZ) Dose A at pre-specified time points during the study.
Drug: bimekizumab
Study participants randomized to this arm will receive bimekizumab (BKZ) Dose B at pre-specified time points during the study.
Drug: bimekizumab
Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.
Also known as: BKZ, UCB4940
Plasma Concentration of Bimekizumab at Week 0
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 0. PK-PPS = Pharmacokinetic per-protocol set, IMP = investigational medicinal product.
Time frame: Baseline (Week 0)
Plasma Concentration of Bimekizumab at Week 1
Blood samples were collected to determine the bimekizumab plasma concentration at Week 1.
Time frame: Week 1
Plasma Concentration of Bimekizumab at Week 4
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 4.
Time frame: Week 4
Plasma Concentration of Bimekizumab at Week 8
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 8.
Time frame: Week 8
Plasma Concentration of Bimekizumab at Week 12
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 12.
Time frame: Week 12
Plasma Concentration of Bimekizumab at Week 16
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 16.
Time frame: Week 16
Plasma Concentration of Bimekizumab at Week 20
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 20.
Time frame: Week 20
Plasma Concentration of Bimekizumab at Week 40
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 40.
Time frame: Week 40
Plasma Concentration of Bimekizumab at Week 64
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 64.
Time frame: Week 64
Plasma Concentration of Bimekizumab at Week 88
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 88.
Time frame: Week 88
Plasma Concentration of Bimekizumab at Week 112
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 112.
Time frame: Week 112
Plasma Concentration of Bimekizumab at Week 124
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 124.
Time frame: Week 124
Plasma Concentration of Bimekizumab at Safety Follow up (SFU)
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 140 (SFU).
Time frame: Week 140 (SFU)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. The last dose was given 4 weeks prior end of extension period.
Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)]
Percentage of Participants With Serious Treatment-emergent Adverse Events
An serious adverse event (SAE) must meet 1 or more of the following criteria: Results in death; Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. The data was rounded to one decimal place. The last dose was given 4 weeks prior end of extension period.
Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Discontinuation of Investigational Medicinal Product (IMP)
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason. The last dose was given 4 weeks prior end of extension period.
Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. This measure considers any TEAEs leading to withdrawal from the study. The last dose was given 4 weeks prior end of extension period.
Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
Exposure-adjusted Incidence Rates (EAIR) of Selected Safety Topics of Interest
Selected safety topics of interest (including infection \[serious, opportunistic, fungal, and tuberculosis (TB)\], inflammatory bowel disease \[IBD\], and injection site reactions) with onset occurring from day of first dose through 20 weeks after final dose of IMP adjusted by duration of participant exposure to IMP. The exposure-adjusted incidence rate (EAIR) is defined as the number of participants (n) with a specific AE adjusted for the exposure and was scaled to 100 participant-years. The last dose was given 4 weeks prior end of extension period.
Time frame: From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140)
Change From Baseline in Vital Signs (Systolic and Diastolic Blood Pressure)
Blood pressure was measured in millimeters of mercury (mmHg).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Vital Signs (Pulse Rate)
Pulse rate was measured in beats per minute (beats/min).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Vital Signs (Temperature)
Temperature (oral, axillary, otic or non-contact forehead) was measured in degrees Celsius (°C).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Hematology Parameters (Platelet Count)
Platelets was measured in number of platelets per liter (10\^9/L).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Hematology Parameters (Mean Corpuscular Hemoglobin)
Mean corpuscular hemoglobin (HGB) was measured in picograms (pg).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Hematology Parameters (Mean Corpuscular Volume)
Mean corpuscular volume was measured in femtolitres.
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Hematology Parameters (Erythrocytes)
Erythrocytes was measured in number of red blood cells per liter (10\^12/L).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Hematology Parameters (Hemoglobin)
Hemoglobin was measured in grams per liter.
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Hematology Parameters (Hematocrit)
Hematocrit was measured in volume percentage (%) of red blood cells in the blood.
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Clinical Chemistry Parameters (Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase)
Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase was measured in units per liter.
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Hematology Parameters (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes)
Basophils, eosinophils, lymphocytes, monocytes, neutrophils and leukocytes was measured in number of white blood cells per liter (10\^9/L).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Clinical Chemistry Parameters (Calcium, Potassium, Sodium, Blood Urea Nitrogen, Glucose (Nonfasting)
Calcium, potassium, sodium, blood urea nitrogen, and glucose (non fasting) was measured in millimoles per liter (mmol/L).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Clinical Chemistry Parameters (Creatinine, Total and Direct Bilirubin)
Creatinine and bilirubin was measured in micromols per liter (μmol/L).
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Clinical Chemistry Parameters (Total Protein)
Total protein was measured in gram per liter (g/L)
Time frame: Baseline (Week 0), Weeks 16, 124, Safety Follow-Up (up to Week 140)
Change From Baseline in Height
Growth assessment, as assessed by the change from Baseline in height.
Time frame: Baseline (Week 0), Weeks 16, 124
Change From Baseline in Weight
Growth assessment, as assessed by the change from Baseline in weight.
Time frame: Baseline (Week 0), Weeks 16, 124
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Percentage of participants with PASI 90 response at Week 16 is reported. PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. This is scoring system that averages redness, thickness, and scaliness of psoriatic lesions(on a 0-4 scale), and weights resulting score by area of skin involved. Body divided into 4 areas:head, arms, trunk to groin, and legs to top of buttocks. Assignment of average score for redness, thickness, and scaling for each of 4 body areas with score of 0(none) to 4(very marked). Determining percentage of skin covered with psoriasis(PSO) for each of body areas and converting to 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved PSO area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Data was rounded to one decimal place.
Time frame: Week 16
Percentage of Participants With Investigator's Global Assessment (IGA) 0/1 (Clear [0]/Almost Clear [1] With at Least 2-category Improvement From Baseline) Response at Week 16
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response (Clear or Almost Clear) is defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline. The data was rounded to one decimal place.
Time frame: Week 16
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 Response at Week 4
Percentage of participants with PASI75 response at Week 4 is reported. PASI75 response assessments are based on at least 75% improvement in PASI score from Baseline. This is scoring system that averages redness, thickness, and scaliness of psoriatic lesions (on a 0-4 scale), and weights resulting score by area of skin involved. Body divided into 4 areas:head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of 4 body areas with a score of 0 (clear) to 4 (very marked). Determining percentage of skin covered with PSO for each of body areas and converting to 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Data was rounded to one decimal place.
Time frame: Week 4
Percentage of Participants With Anti-bimekizumab Antibody (AbAb) Detection Prior to Investigational Medicinal Product (IMP) Administration
Anti-bimekizumab antibody (AbAb) detection prior to IMP administration. Anti-bimekizumab antibodies was measured using 3-tiered assay approach: screening assay, confirmatory assay, and titration assay. Antidrug antibody (ADAb) positive status: any sample that is positive screen and positive immunodepletion (regardless of availability of a titer value). ADAb negative status: any sample that is either negative screen, or positive screen and negative immunodepletion, and where the bimekizumab concentration is less than or equal to the drug tolerance limit of the validated ADAb assay. ADAb missing status: any sample that is either negative screen or positive screen and negative immunodepletion and where the bimekizumab concentration exceeds the validated ADAb assay drug tolerance limit.
Time frame: Baseline (Week 0)
Percentage of Participants With Anti-bimekizumab Antibody (AbAb) Detection Following Investigational Medicinal Product (IMP) Administration
Anti-bimekizumab antibody (AbAb) detection following IMP administration. Overall ADAb positive is defined as having at least one sample that is confirmed positive following the 1st dose of IMP to SFU (regardless of missing data). Overall ADAb negative is defined as having all samples reported as negative, or has only one missing/inconclusive sample, following the 1st dose of IMP to SFU. Overall ADAb missing if the study participant has more than one missing ADAb sample for any reason and all other available ADAb samples are negative. The data was rounded to one decimal place.
Time frame: From Baseline (Week 0, post-first dose) to Safety Follow-Up (Week 140)
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Response at Week 16
The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week, (ie, over the last 7 days). The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).
Time frame: Baseline, Week 16
The study started to enroll participants in April 2021 and concluded in March 2025.
| Milestone | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Started | 20 | 21 |
| Completed | 19 | 21 |
| Not completed | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Milestone | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Started | 19 | 20 |
| Completed | 17 | 19 |
| Not completed | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Consent withdrawn by participant (not due to ae) | 1 | 0 |
| Withdrew: The patient left to study in the usa | 1 | 0 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 0. PK-PPS = Pharmacokinetic per-protocol set, IMP = investigational medicinal product.
| microgram per milliliter (µg/mL) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 0 | NA ± NA | NA ± NA |
Blood samples were collected to determine the bimekizumab plasma concentration at Week 1.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 1 | 21.145 ± 33.510 | 3.811 ± 30.424 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 4.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 4 | 11.718 ± 35.259 | 1.986 ± 22.888 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 8.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 8 | 16.344 ± 39.386 | 2.562 ± 91.934 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 12.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 12 | 19.312 ± 38.235 | 2.600 ± 89.916 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 16.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 16 | 20.163 ± 41.323 | 2.560 ± 99.017 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 20.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 20 | 21.579 ± 38.806 | 2.689 ± 99.146 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 40.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 40 | 20.404 ± 48.700 | 3.354 ± 115.576 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 64.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 64 | 23.177 ± 42.505 | 3.339 ± 106.934 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 88.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 88 | 20.342 ± 42.584 | 2.928 ± 107.926 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 112.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 112 | 18.770 ± 50.422 | 3.017 ± 109.444 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 124.
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Week 124 | 17.495 ± 40.714 | 3.104 ± 107.492 |
Blood samples were collected prior to the scheduled dose to determine the bimekizumab plasma concentration at Week 140 (SFU).
| µg/mL | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Plasma Concentration of Bimekizumab at Safety Follow up (SFU) | 0.762 ± 166.309 | NA ± NA |
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. The last dose was given 4 weeks prior end of extension period.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 85.0 | 81.0 |
An serious adverse event (SAE) must meet 1 or more of the following criteria: Results in death; Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent disability/incapacity; Is a congenital anomaly/birth defect; Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or subject and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. The data was rounded to one decimal place. The last dose was given 4 weeks prior end of extension period.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Percentage of Participants With Serious Treatment-emergent Adverse Events | 10.0 | 14.3 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. This measure considers any TEAE leading to permanent discontinuation of IMP regardless of reason. The last dose was given 4 weeks prior end of extension period.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Discontinuation of Investigational Medicinal Product (IMP) | 5.0 | 0 |
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP. Treatment-emergent AEs are defined as those AEs that started date on or following the first dose of IMP through the final dose of IMP +20 weeks. This measure considers any TEAEs leading to withdrawal from the study. The last dose was given 4 weeks prior end of extension period.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From the Study | 0 | 0 |
Selected safety topics of interest (including infection \[serious, opportunistic, fungal, and tuberculosis (TB)\], inflammatory bowel disease \[IBD\], and injection site reactions) with onset occurring from day of first dose through 20 weeks after final dose of IMP adjusted by duration of participant exposure to IMP. The exposure-adjusted incidence rate (EAIR) is defined as the number of participants (n) with a specific AE adjusted for the exposure and was scaled to 100 participant-years. The last dose was given 4 weeks prior end of extension period.
| events per 100 participants-years | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Serious infection | 0 | 0 |
| Fungal infection | 4.06 | 0 |
| Opportunistic infection (including TB) | 0 | 0 |
| IBD | 0 | 0 |
| Injection site reactions | 4.35 | 0 |
Blood pressure was measured in millimeters of mercury (mmHg).
| millimetre of mercury (mmHg) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Systolic Blood Pressure-Week 16 | 1.9 ± 8.7 | -2.1 ± 10.1 |
| Systolic Blood Pressure-Week 124 | -0.2 ± 13.4 | -2.1 ± 9.5 |
| Systolic Blood Pressure-SFU | 2.7 ± 17.5 | 0.8 ± 11.3 |
| Diastolic Blood Pressure-Week 16 | -0.1 ± 9.2 | -1.7 ± 7.8 |
| Diastolic Blood Pressure-Week 124 | -0.9 ± 9.9 | -1.2 ± 6.9 |
| Diastolic Blood Pressure-SFU | 0.5 ± 5.8 | -4.0 ± 5.5 |
Pulse rate was measured in beats per minute (beats/min).
| beats/min | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -1.1 ± 11.7 | -3.2 ± 9.5 |
| Week 124 | -3.0 ± 16.9 | -1.4 ± 13.7 |
| SFU | -5.2 ± 16.2 | -10.3 ± 15.5 |
Temperature (oral, axillary, otic or non-contact forehead) was measured in degrees Celsius (°C).
| celsius (°C) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -0.06 ± 0.33 | 0.10 ± 0.25 |
| Week 124 | -0.19 ± 0.32 | -0.09 ± 0.19 |
| SFU | -0.13 ± 0.31 | 0.00 ± 0.18 |
Platelets was measured in number of platelets per liter (10\^9/L).
| cells*10^9/L | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -3.1 ± 29.3 | 3.6 ± 37.3 |
| Week 124 | -12.1 ± 58.9 | -8.1 ± 32.4 |
| SFU | -34.1 ± 54.8 | -29.5 ± 22.4 |
Mean corpuscular hemoglobin (HGB) was measured in picograms (pg).
| picograms (pg) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -0.03 ± 0.64 | -0.14 ± 0.64 |
| Week 124 | 0.54 ± 1.37 | 0.02 ± 1.17 |
| SFU | 1.32 ± 1.41 | -0.20 ± 0.52 |
Mean corpuscular volume was measured in femtolitres.
| femtoliters | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -1.22 ± 2.41 | -1.57 ± 2.13 |
| Week 124 | 1.42 ± 4.08 | -0.23 ± 4.35 |
| SFU | 3.54 ± 3.95 | 1.98 ± 2.66 |
Erythrocytes was measured in number of red blood cells per liter (10\^12/L).
| cells*10^12/L | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -0.011 ± 0.288 | 0.039 ± 0.193 |
| Week 124 | -0.013 ± 0.323 | -0.017 ± 0.211 |
| SFU | -0.152 ± 0.364 | -0.143 ± 0.151 |
Hemoglobin was measured in grams per liter.
| grams per liter | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -0.5 ± 7.4 | 0.4 ± 4.6 |
| Week 124 | 2.2 ± 12.0 | -0.4 ± 8.6 |
| SFU | 1.9 ± 15.7 | -5.0 ± 2.9 |
Hematocrit was measured in volume percentage (%) of red blood cells in the blood.
| % of Red Blood Cells in the blood | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -0.72 ± 2.43 | -0.39 ± 1.85 |
| Week 124 | 0.61 ± 3.79 | -0.20 ± 3.09 |
| SFU | 0.32 ± 4.64 | -0.38 ± 1.47 |
Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase was measured in units per liter.
| units per liter | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Alkaline phosphatase-Week 16 | -2.0 ± 21.8 | -2.4 ± 23.5 |
| Alkaline phosphatase-Week 124 | -52.5 ± 86.8 | -22.3 ± 47.9 |
| Alkaline phosphatase-SFU | -80.1 ± 115.5 | -19.0 ± 70.1 |
| Alanine aminotransferase-Week 16 | 2.9 ± 10.7 | -1.9 ± 4.4 |
| Alanine aminotransferase-Week 124 | 9.1 ± 18.1 | -0.6 ± 5.8 |
| Alanine aminotransferase-SFU | -0.4 ± 9.8 | -4.0 ± 9.6 |
| Aspartate aminotransferase-Week 16 | 1.4 ± 3.6 | -1.9 ± 4.7 |
| Aspartate aminotransferase-Week 124 | 2.6 ± 8.0 | -1.7 ± 5.7 |
| Aspartate aminotransferase-SFU | -0.7 ± 8.6 | -1.8 ± 4.9 |
Basophils, eosinophils, lymphocytes, monocytes, neutrophils and leukocytes was measured in number of white blood cells per liter (10\^9/L).
| cells*10^9/L | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Basophils-Week 16 | -0.002 ± 0.032 | -0.007 ± 0.027 |
| Basophils-Week 124 | 0.001 ± 0.036 | -0.006 ± 0.029 |
| Basophils-SFU | -0.032 ± 0.049 | 0.005 ± 0.013 |
| Eosinophils-Week 16 | -0.052 ± 0.267 | 0.006 ± 0.067 |
| Eosinophils-Week 124 | 0.001 ± 0.157 | -0.006 ± 0.124 |
| Eosinophils-SFU | -0.083 ± 0.089 | -0.050 ± 0.054 |
| Lymphocytes-Week 16 | 0.025 ± 0.407 | -0.105 ± 0.537 |
| Lymphocytes-Week 124 | 0.057 ± 0.705 | -0.222 ± 0.710 |
| Lymphocytes-SFU | -0.124 ± 0.573 | -0.233 ± 0.378 |
| Monocytes-Week 16 | -0.069 ± 0.195 | -0.052 ± 0.141 |
| Monocytes-Week 124 | -0.064 ± 0.256 | -0.047 ± 0.156 |
| Monocytes-SFU | -0.112 ± 0.142 | 0.063 ± 0.167 |
| Neutrophils-Week 16 | -0.628 ± 1.145 | -0.610 ± 1.922 |
| Neutrophils-Week 124 | -0.522 ± 1.457 | -0.623 ± 2.342 |
| Neutrophils-SFU | -0.109 ± 1.520 | -0.298 ± 0.721 |
| Leukocytes-Week 16 | -0.726 ± 1.445 | -0.763 ± 2.247 |
| Leukocytes-Week 124 | -0.531 ± 2.038 | -0.904 ± 2.645 |
| Leukocytes-SFU | -0.460 ± 1.663 | -0.505 ± 1.244 |
Calcium, potassium, sodium, blood urea nitrogen, and glucose (non fasting) was measured in millimoles per liter (mmol/L).
| millimoles per liter (mmol/L) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Calcium-Week 16 | 0.014 ± 0.094 | 0.009 ± 0.231 |
| Calcium-Week 124 | -0.044 ± 0.125 | -0.013 ± 0.106 |
| Calcium-SFU | 0.003 ± 0.105 | -0.058 ± 0.066 |
| Potassium-Week 16 | 0.08 ± 0.20 | 0.20 ± 0.62 |
| Potassium-Week 124 | 0.04 ± 0.39 | -0.05 ± 0.31 |
| Potassium-SFU | 0.04 ± 0.32 | -0.06 ± 0.36 |
| Sodium-Week 16 | -0.2 ± 2.0 | 0.7 ± 1.6 |
| Sodium-Week 124 | 0.1 ± 1.5 | -0.5 ± 1.6 |
| Sodium-SFU | 1.1 ± 1.8 | 0.2 ± 1.8 |
| Blood urea nitrogen-Week 16 | 0.07 ± 1.01 | 0.02 ± 1.12 |
| Blood urea nitrogen-Week 124 | 0.44 ± 1.10 | -0.18 ± 1.20 |
| Blood urea nitrogen-SFU | 0.61 ± 1.48 | -0.04 ± 1.35 |
| Glucose: Week 16 | -0.039 ± 0.632 | 0.115 ± 0.492 |
| Glucose: Week 124 | -0.291 ± 0.655 | 0.323 ± 0.746 |
| Glucose: SFU | -0.138 ± 0.766 | 0.270 ± 0.593 |
Creatinine and bilirubin was measured in micromols per liter (μmol/L).
| μmol/L | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Creatinine-Week 16 | -0.82 ± 9.40 | 1.85 ± 4.89 |
| Creatinine-Week 124 | 7.31 ± 11.30 | 8.23 ± 6.38 |
| Creatinine-SFU | 9.83 ± 9.51 | 7.94 ± 5.26 |
| Direct Bilirubin-Week 16 | -0.27 ± 1.66 | -0.02 ± 1.21 |
| Direct Bilirubin-Week 124 | 0.69 ± 1.96 | -0.12 ± 0.88 |
| Direct Bilirubin-SFU | -0.43 ± 1.05 | 0.63 ± 0.46 |
| Total bilirubin-Week 16 | -0.57 ± 4.51 | 0.05 ± 2.94 |
| Total bilirubin-Week 124 | 2.36 ± 6.30 | 0.27 ± 2.71 |
| Total bilirubin-SFU | -0.80 ± 3.61 | 2.08 ± 2.32 |
Total protein was measured in gram per liter (g/L)
| g/L | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | -0.2 ± 3.4 | 0.1 ± 3.9 |
| Week 124 | 1.1 ± 4.6 | 0.7 ± 3.8 |
| SFU | -0.2 ± 3.4 | -1.8 ± 4.2 |
Growth assessment, as assessed by the change from Baseline in height.
| centimeter (cm) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | 0.61 ± 1.59 | 0.56 ± 1.67 |
| Week 124 | 4.01 ± 6.53 | 3.04 ± 5.34 |
Growth assessment, as assessed by the change from Baseline in weight.
| kilogram (kg) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Week 16 | 2.62 ± 3.20 | 0.71 ± 4.11 |
| Week 124 | 4.01 ± 5.99 | 5.88 ± 9.64 |
Percentage of participants with PASI 90 response at Week 16 is reported. PASI90 response assessments are based on at least 90% improvement in PASI score from Baseline. This is scoring system that averages redness, thickness, and scaliness of psoriatic lesions(on a 0-4 scale), and weights resulting score by area of skin involved. Body divided into 4 areas:head, arms, trunk to groin, and legs to top of buttocks. Assignment of average score for redness, thickness, and scaling for each of 4 body areas with score of 0(none) to 4(very marked). Determining percentage of skin covered with psoriasis(PSO) for each of body areas and converting to 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved PSO area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Data was rounded to one decimal place.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Percentage of Participants With Psoriasis Area and Severity Index (PASI) 90 Response at Week 16 | 95.0 | 90.5 |
The Investigator's Global Assessment (IGA) measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= clear, no signs of psoriasis; presence of post-inflammatory hyperpigmentation, scale 1= almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= mild thickening, pink to light red coloration and predominately fine scaling, 3= moderate, clearly distinguishable to moderate thickening; dull to bright red, clearly distinguishable to moderate thickening; moderate scaling and 4= severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions. IGA response (Clear or Almost Clear) is defined as clear \[0\] or almost clear \[1\] with at least a two-category improvement from Baseline. The data was rounded to one decimal place.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Percentage of Participants With Investigator's Global Assessment (IGA) 0/1 (Clear [0]/Almost Clear [1] With at Least 2-category Improvement From Baseline) Response at Week 16 | 95.0 | 90.5 |
Percentage of participants with PASI75 response at Week 4 is reported. PASI75 response assessments are based on at least 75% improvement in PASI score from Baseline. This is scoring system that averages redness, thickness, and scaliness of psoriatic lesions (on a 0-4 scale), and weights resulting score by area of skin involved. Body divided into 4 areas:head, arms, trunk to groin, and legs to top of buttocks. Assignment of an average score for redness, thickness, and scaling for each of 4 body areas with a score of 0 (clear) to 4 (very marked). Determining percentage of skin covered with PSO for each of body areas and converting to 0 to 6 scale. Final PASI=average redness, thickness, and scaliness of psoriatic skin lesions, multiplied by involved psoriasis area score of respective section, and weighted by percentage of person's affected skin for respective section. Minimum possible PASI score is 0=no disease, maximum score is 72=maximal disease. Data was rounded to one decimal place.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 Response at Week 4 | 80.0 | 52.4 |
Anti-bimekizumab antibody (AbAb) detection prior to IMP administration. Anti-bimekizumab antibodies was measured using 3-tiered assay approach: screening assay, confirmatory assay, and titration assay. Antidrug antibody (ADAb) positive status: any sample that is positive screen and positive immunodepletion (regardless of availability of a titer value). ADAb negative status: any sample that is either negative screen, or positive screen and negative immunodepletion, and where the bimekizumab concentration is less than or equal to the drug tolerance limit of the validated ADAb assay. ADAb missing status: any sample that is either negative screen or positive screen and negative immunodepletion and where the bimekizumab concentration exceeds the validated ADAb assay drug tolerance limit.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Positive | 0 | 0 |
| Negative | 95.0 | 100 |
| Missing | 5.0 | 0 |
Anti-bimekizumab antibody (AbAb) detection following IMP administration. Overall ADAb positive is defined as having at least one sample that is confirmed positive following the 1st dose of IMP to SFU (regardless of missing data). Overall ADAb negative is defined as having all samples reported as negative, or has only one missing/inconclusive sample, following the 1st dose of IMP to SFU. Overall ADAb missing if the study participant has more than one missing ADAb sample for any reason and all other available ADAb samples are negative. The data was rounded to one decimal place.
| percentage of participants | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Overall ADAb positive status up to SFU | 68.4 | 45.0 |
| Overall ADAb negative status up to SFU | 26.3 | 55.0 |
| Overall ADAb Missing status up to SFU | 5.3 | 0 |
The CDLQI is a questionnaire designed to measure the impact of skin diseases on the lives of children. The questionnaire consists of 10 questions that are based on the experiences of children with skin disease. The instrument asks participants about symptoms and feelings, leisure, school or holidays, personal relationships, sleep, and treatment. The questions relate to the impact of the skin disease on the child over the last week, (ie, over the last 7 days). The CDLQI total score ranges from 0 to 30 with higher scores indicating higher impact of skin disease on quality of life (Qol).
| Scores on a scale | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) Response at Week 16 | -3.9 ± 5.8 | -5.5 ± 6.4 |
Collected over From day of first dose (Week 0) through 20 weeks after final dose of IMP (up to Week 140). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BKZ Dose A (320/160 mg) | 0/20 (0%) | 2/20 (10%) | 17/20 (85%) |
| BKZ Dose B (64/32 mg) | 0/21 (0%) | 3/21 (14.3%) | 17/21 (81%) |
| Event | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| False positive tuberculosis testInvestigations | 1/20 | 0/21 |
| SyncopeNervous system disorders | 1/20 | 0/21 |
| Intentional product misuseInjury, poisoning and procedural complications | 0/20 | 1/21 |
| Generalised tonic-clonic seizureNervous system disorders | 0/20 | 1/21 |
| EpilepsyNervous system disorders | 0/20 | 1/21 |
| Suicidal ideationPsychiatric disorders | 0/20 | 1/21 |
| Event | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) |
|---|---|---|
| NasopharyngitisInfections and infestations | 9/20 | 7/21 |
| Urinary tract infectionInfections and infestations | 5/20 | 3/21 |
| Upper respiratory tract infectionInfections and infestations | 2/20 | 5/21 |
| PharyngitisInfections and infestations | 2/20 | 3/21 |
| Injection site erythemaGeneral disorders | 2/20 | 0/21 |
| RhinitisInfections and infestations | 2/20 | 0/21 |
| ConjunctivitisInfections and infestations | 2/20 | 1/21 |
| Tinea pedisInfections and infestations | 2/20 | 0/21 |
| Limb injuryInjury, poisoning and procedural complications | 2/20 | 0/21 |
| Alanine aminotransferase increasedInvestigations | 2/20 | 0/21 |
Baseline Characteristics refer to the RS which consisted of all randomized participants.
| Age, Continuous(years) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) | Total |
|---|---|---|---|
| Mean | 15.1 ± 1.9 | 14.6 ± 2.0 | 14.8 ± 1.9 |
| Age, Customized(Participants) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) | Total |
|---|---|---|---|
| 12 - <18 years | 20 | 21 | 41 |
| Sex: Female, Male(Participants) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) | Total |
|---|---|---|---|
| Female | 11 | 13 | 24 |
| Male | 9 | 8 | 17 |
| Race/Ethnicity, Customized(Participants) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) | Total |
|---|---|---|---|
| Black | 1 | 0 | 1 |
| White | 19 | 21 | 40 |
| Race/Ethnicity, Customized(Participants) | BKZ Dose A (320/160 mg) | BKZ Dose B (64/32 mg) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 20 | 20 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Apr 2021 to primary completion in Mar 2025, 47 months.
Results were first posted in May 2026, 1 year 2 months after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 47 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bimekizumab